Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dynavax Technologies has obtained data from preclinical studies demonstrating that the company's immunostimulatory sequence based influenza vaccine shows potential against pandemic flu.
Subscribe to our email newsletter
The data show that the vaccine induces an immune response potentially capable of eradicating cells infected by highly divergent influenza viruses. It also has the potential to augment the protective antibody response generated by standard flu vaccine.
These combined responses may provide effective immunity against multiple strains of the flu virus and may represent a potent new vaccine approach against divergent or pandemic strains of the flu virus.
In 2003, Dynavax was awarded a $3 million grant over three and a half years to fund R&D of a pandemic influenza vaccine under a program for biodefense administered by the National Institute of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health.
This funding should enable Dynavax to complete preclinical feasibility experiments and manufacturing of sufficient GMP-grade materials for investigational new drug (IND)-enabling toxicology studies.